Jankowski A, Karwowski J, Marzec A, Kretowicz W, Nartowicz E
Zakładu Biofarmacji Centrum Medycznego Kształcenia Podyplomowego w Bydgoszczy.
Kardiol Pol. 1990 Feb;33(2):116-21.
During last few years were reports concerning a new endogenous digoxin -like immunologic factor (DLIF) in patients not receiving digitalis. DLIF was stated in pregnant women's blood umbilical and neonatal blood as well as in patients with renal failure or hepatopathy. This phenomenon could be related to hormones changes (pregnancy) as well as alterations of cholesterol, triglycerides, free fatty acids, albumins or total protein level (nephropathy, hepatopathy). DLIF overstated determination of serum digoxin concentration, which in the case of exceptional narrow digoxin therapeutic spectrum as well as its concentration-dependent toxicity became a significant clinical problem. Effect extent of DLIF on serum digoxin level could be also related to applied analytic technics. The aim of the study was to compare two routinely applying analytic methods: polarized immunofluorescence (FPIA-TDx Abbott) with radioimmunological assay (RIA). The study was performed in patients with renal failure to estimate DLIF effect on real serum digoxin concentration as well as on extent and DLIF elimination velocity during dialysis. DLIF occurrence in patients with renal failure not receiving digitalis was experimentally stated using both RIA and FPIA methods. However, RIA revealed DLIF in all cases: before and after dialysis as well as in not dialyzed patients with a concentration above 0.3 ng/ml, when FPIA values were respectively: 0.087; 0.043; 0.078 ng/ml, which was less than 10% of digoxine therapeutic range (0.9-2.0 ng/ml). DLIF lowered in a course of dialysis to FPIA advantage, which was proved by FPIA/RIA ratio decrease nearly of a half of its predialysis value. Pre- and postdialysis values of FPIA/RIA ratio were 0,204 and 0,134 respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
在过去几年里,有关于未接受洋地黄治疗的患者体内存在一种新的内源性类地高辛免疫因子(DLIF)的报道。DLIF存在于孕妇血液、脐带血和新生儿血液中,以及肾衰竭或肝病患者体内。这种现象可能与激素变化(怀孕)以及胆固醇、甘油三酯、游离脂肪酸、白蛋白或总蛋白水平的改变(肾病、肝病)有关。DLIF会高估血清地高辛浓度的测定值,鉴于地高辛治疗谱极窄且具有浓度依赖性毒性,这成为了一个重大的临床问题。DLIF对血清地高辛水平的影响程度也可能与所应用的分析技术有关。该研究的目的是比较两种常规应用的分析方法:偏振免疫荧光法(雅培公司的FPIA - TDx)和放射免疫分析法(RIA)。该研究在肾衰竭患者中进行,以评估DLIF对实际血清地高辛浓度的影响,以及透析过程中DLIF的程度和清除速度。使用RIA和FPIA方法通过实验证实了未接受洋地黄治疗的肾衰竭患者体内DLIF的存在。然而,RIA在所有情况下都检测到了DLIF:透析前、透析后以及未透析患者中,其浓度均高于0.3 ng/ml,而FPIA测定值分别为:0.087;0.043;0.078 ng/ml,低于地高辛治疗范围(0.9 - 2.0 ng/ml)的10%。在透析过程中,DLIF降低至FPIA占优势,这通过FPIA/RIA比值降低至透析前值的近一半得到证实。透析前和透析后FPIA/RIA比值分别为0.204和0.134。(摘要截断于250字)